News from cantargia ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

10 Oct, 2019, 11:30 BST Cantargia Reports Filing of Opposition Against Cantargia Patent in Europe

Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia's patent family covering antibody...


04 Sep, 2019, 14:39 BST Cantargia Submits Request for pre-IND Meeting on CAN04 With US FDA

Cantargia AB today announced that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the...


23 Aug, 2019, 12:09 BST Cantargia Announce Positive Preclinical Data on CAN04 in Bladder Cancer

Cantargia AB today announce new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The ...


23 Aug, 2019, 07:47 BST Cantargia and BioWa Extend Ongoing Collaboration Around the POTELLIGENT® Technology

Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of...


22 Aug, 2019, 07:55 BST Cantargia Publishes Half Year Report

Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page...


04 Jul, 2019, 08:01 BST Cantargia Announce Full Recruitment of CAN04 Monotherapy arm in Ongoing Phase IIa Clinical Trial

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as...


02 Jun, 2019, 17:37 BST Cantargia: Presentation of Phase I Clinical Data on Antibody CAN04 at ASCO

New phase I clinical data on Cantargia´s antibody CAN04 (nidanilimab) were presented today in an oral session at the 2019 ASCO Annual Meeting. Data...


27 May, 2019, 18:06 BST Annual General Meeting in Cantargia AB (publ)

Cantargia's Annual General Meeting on 27 May 2019 resolved in accordance with the following: That no dividend would be paid; To discharge the board...


27 May, 2019, 07:38 BST Cantargia Publishes Interim Report for First Quarter 2019

Cantargia AB's ("Cantargia") interim report for first quarter 2019 is now available on the company's web page...


15 May, 2019, 23:36 BST Cantargia: Abstract Published for the Oral Presentation of Antibody CAN04 Phase I Data at ASCO

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is...


14 May, 2019, 07:43 BST Cantargia Announces New Pre-clinical Results Showing Consistent Positive Effects of the Antibody CAN04 When Combined with Platinum-based Chemotherapies

Cantargia AB today announces new pre-clinical results from the antibody CAN04 (nidanilimab) in combination with platinum-based chemotherapies....


13 May, 2019, 07:40 BST Cantargia Signs Agreement With Patheon Biologics B.V. for Production of Antibody CAN04

Cantargia AB (publ) and Patheon Biologics B.V. (part of ThermoFischer Scientific) have signed an agreement regarding future production of the...


30 Apr, 2019, 08:01 BST New Number of Shares and Votes in Cantargia

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see...


26 Apr, 2019, 15:14 BST Notice of Annual General Meeting in Cantargia AB (publ)

The shareholders of Cantargia AB (publ) are invited to the Annual General Meeting on Monday, 27 May 2019, at 4 p.m. CET at Medicon Village,...


18 Apr, 2019, 08:35 BST Cantargia Phase I Clinical Results on the Antibody CAN04 Selected for Oral Presentation at ASCO

Cantargia AB today announce that the phase I clinical data generated by the antibody CAN04 will be presented orally at the 2019 Annual ASCO meeting...


21 Mar, 2019, 19:45 GMT Cantargia Makes a Directed Share Issue of Approximately SEK 106 Million for Increased Investments in the Clinical Development of CAN04

The board of directors of Cantargia AB (publ) has resolved, pursuant to the general meeting's authorization, on a directed share issue of...


27 Feb, 2019, 07:51 GMT Cantargia Publishes Year end Report for 2018

antargia AB's ("Cantargia") year end report for 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports....


25 Jan, 2019, 07:44 GMT Cantargia: First Patient Treated With Antibody CAN04 in the Phase IIa Part of CANFOUR Trial

antargia AB (publ) today announce that the first patient in the phase IIa part of the CANFOUR clinical trial has received CAN04 (nidanilimab)...


10 Dec, 2018, 08:07 GMT Cantargia Presents New Positive Preclinical Data on Antibody CAN04 at Major Antibody Conference

antargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference...


07 Dec, 2018, 14:39 GMT Cantargia: Phase I Safety Evaluation Part of CANFOUR Trial of Antibody CAN04 Completed and Phase IIa Part Being Initiated

Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation...


15 Nov, 2018, 07:38 GMT Cantargia Publishes Interim Report for Third Quarter of 2018

Cantargia AB's interim report for the third quarter of 2018 is now available on the company's web page...


30 Oct, 2018, 12:17 GMT Cantargia AB: Nomination Committee Appointed Ahead of 2019 Annual General Meeting

Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2019 Annual General Meeting, and...


20 Oct, 2018, 14:04 BST Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO

The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose Effects on biomarkers and 5 of 13 evaluable patients achieved stable disease 10...


09 Oct, 2018, 07:46 BST Cantargia Presents Clinical Data From its Ongoing CANFOUR Trial at ESMO

Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented...


01 Oct, 2018, 07:44 BST Cantargia Obtains Patent in USA for the Antibody CAN03

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company's patent application 15/501,710...